Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
Description
The incidence of severe immune-related adverse events (irAEs) in cancer subjects receiving immune checkpoint inhibitors (ICIs) following COVID-19 vaccination and the relationship between the incidence of severe irAE and the interval between COVID-19
